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Abstract
The interaction between the arginine glycine and aspartic acid motif (RGD) of integrin ligands
such as vitronectin and the integrin receptor αVβ3 in mediating cell attachment has been well
described. Similarly, the ability of disintegrins, small RGD containing peptides, to inhibit cell
attachment and other cellular processes has also been studied extensively. Recently, we
characterized a second site of interaction between vitronectin and its integrin partner. We
determined that amino acids within the heparin binding domain of vitronectin bind to a cysteine
loop (C-loop) region of β3 and that this interaction is required for the positive effects of αVβ3
ligand occupancy on IGF-I signaling in smooth muscle cells. In this study we examine the
signaling events activated following ligand binding of disintegrins to the αVβ3 and the ability of
these signals to be regulated by binding of the heparin binding domain of vitronectin. We
demonstrate that disintegrin ligand binding activates a series of events including the sequential
activation of the tyrosine kinases c-Src and Syk. This leads to the activation of calpain and the
cleavage of the β3 cytoplasmic tail. Addition of vitronectin or a peptide homologous to the heparin
binding domain inhibited activation of this pathway.
Our results suggest that the signaling events that occur following ligand binding to the αVβ3
integrin reflects a balance between the effects mediated through the RGD binding site interaction
and the effects mediated by the heparin binding site interaction and that for intact vitronectin the




Integrins are heterodimeric proteins consisting of one α and one β subunit. 16 α- and 8 β-
subunits have been identified that can form more than 20 functional combinations (reviewed
by Aplin et al [Aplin et al., 1998; Aplin et al., 1999]. Association of integrin receptors and
their ligands is required for cells to stably attach and spread to the extracellular matrix.
Furthermore, ligand binding of integrins to their ligands is required for most cell types to
respond to growth and survival factors[Aplin et al., 1998; Aplin et al., 1999]. Smooth
muscle cells (SMC), proliferating endothelial cells, osteoclasts and certain types of
malignant cells have been shown to express the highest levels of the αVβ3 integrin. We have
been particularly interested in the role of ligand binding to the αVβ3 integrin in the
regulation of the SMC response to the growth factor insulin like growth factor — I (IGF-I)
[Jones et al., 1996; Maile et al., 2001; Zheng and Clemmons, 1998]. We have shown that the
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ability of IGF-I to stimulate migration and proliferation of SMC is dependent upon αVβ3
ligand occupancy [Jones et al., 1996; Maile et al., 2001; Zheng and Clemmons, 1998]. When
SMC are deprived of a source of vitronectin (Vn) or if Vn binding to αVβ3 is blocked by the
addition of an anti-αVβ3 antibody then they do not respond to IGF-I. Conversely, the
addition of Vn enhances both the proliferation and migration of these cells in response to
IGF-I. Previous studies have shown that cellular attachment via the αVβ3 integrin requires
an interaction between the arginine glycine and aspartic acid motif (RGD) in its ligands such
as Vn and fibronectin and amino acids tyrosine 122 to methionine 124 of the β3 integrin
subunit [Xiong et al., 2001]. Disruption of this interaction with RGD containing disintegrin
antagonists causes cell detachment and ultimately apoptosis [Blobel and White, 1992;
Niewiarowski et al., 1994]. We have shown in SMC that are stably attached and spread that
addition of disintegrin echistatin, at doses that are low that do not result in cell detachment,
inhibits the response of SMC to IGF-I [Jones et al., 1996; Zheng and Clemmons, 1998].
More recently we identified and characterized a second region of Vn that was required for
the enhancing effects of αVβ3 ligand occupancy on the response of SMC to IGF-I [Maile et
al., 2006a; Maile et al., 2006b]. We determined that the heparin binding domain (HBD) of
Vn (amino acids 365–381), interacted with a region of the β3 extracellular domain referred
to as the cysteine loop region (C-loop; between amino acids 177 and 184) and that this
interaction was required for these enhancing effects. The crystal structure of αVβ3 shows
that the C-loop region is spatially distinct from the critical residues required for RGD
binding domain (amino acids 122 and 124) [Xiong et al., 2001]. The aim of this study was to
determine the signaling events that mediate the inhibitory effects of RGD antagonist binding
to αVβ3, whether these effects could be modulated by binding of the HBD region of Vn to
β3 and the net effect of simultaneous ligand occupancy of both sites.
Material and Methods
Polyvinyl difluoride membranes (Immobilon P) were purchased from Millipore Corporation
(Bedford, MA). Autoradiographic film was obtained from Pierce (Pierce/ThermoFisher,
Rockford, IL). Fetal Bovine Serum, Dulbecco’s modified medium, penicillin and
streptomycin were purchased from Life Technologies, (Grand Island, NY). The calpain 1
polyclonal antibody and the monoclonal phosphotyrosine antibody (PY99) were purchased
from Santa Cruz (Santa Cruz, CA). The anti- FAK [pY397] and the anti-Src kinase [pY418]
phosphospecific polyclonal antibodies were purchased from Biosource International Inc
(Camarillo, CA). The anti-Syk and anti-FAK polyclonal antibodies were purchased from
Upstate Biotechnology (Lake Placid, NY). The antibody against the αV subunit of αVβ3
was purchased from Chemicon International (Temecula, CA). The polyclonal antibody
against β3 was prepared by injecting rabbits with two peptides, one containing amino acids
60–85 and the other 653–680 of porcine β3 sequence that had been conjugated to KLH. The
β3 antibody specific for the cytoplasmic tail of β3 prepared by injecting rabbits with a
peptide containing amino acids 742–762 of β3 (c-β3). The calpain inhibitor E64d, the Syk
inhibitor, piceatannol and the Src family kinase inhibitor PP2 were purchased from
Calbiochem-Novabiochem, (San Diego, CA). All other reagents were purchased from Sigma
Chemical Company (St Louis, MO) unless otherwise stated.
Porcine aortic SMC were isolated as previously described [Gockerman et al., 1995] and
maintained in Dulbecco’s modified medium supplemented with glucose (4.5 gm/liter),
penicillin (100 units/ml), streptomycin (100 µg/ml) (DMEM-H) and 10% Fetal Bovine
serum (FBS) in 10cm tissue culture plates (Falcon Laboratory, Franklin Lakes NJ ). The
cells were used between passage 5 and 16.
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Generation of recombinant wild type (Wt) and mutant forms of Vn
RT-PCR was used to generate the WtVn cDNA from mRNA prepared from porcine SMC
[Yoneda et al., 1996]. Wild-type Vitronectin (WtVn), a form of Vn in which the HBD had
been deleted (VnΔHBD), i.e deletion of amino acids 342–358 (which contains the amino
acid sequence QPKMTKSARRSGKRYRS) and a RGD66E mutant Vn were generated,
purified and characterized as we have described previously [Maile et al., 2006b].
A synthetic peptide corresponding to the HBD (amino acids 365–381) of human Vn [Suzuki
et al., 1984] (LAKKQRFRHRNRKGYRS ) was synthesized, purified and characterized as
we have described previously.
Cell treatments
SMC were plated at a density of 5 × 10 5 in 10 cm dishes (Falcon # 3003) then grown to
90% confluency (approximately 5 × 10 6 cells). SMC were incubated in serum free medium
supplemented with 0.02 % bovine serum albumin (SFM) with or without echistatin (10−8
M), synthetic αVβ3 antagonists (10−6 M), Vn HBD peptide (10 µg/ml) or intact Vn (2 µg/
ml). Where indicated, SMC were preincubated with inhibitors (PP2, 4µM, piceatannol, 30
µM, E64d, 20 µM or calpastatin, 50 µM) or appropriately diluted vehicle (PP2 and
piceatannol = 0.08 % DMSO, E64d and calpastatin = water) for 1 hour prior to the addition
of echistatin.
Cell lysis
Following treatment SMC were lysed in ice-cold lysis buffer: 50 mM Tris HCL (pH 7.5),
150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 1 mM EGTA plus 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 1 mM PMSF, 1 µg/ml pepstatin A, 1 µg/ml
leupeptin, 1 µg/ml aprotinin. The lysates were clarified by centrifugation at 14,000 × g for
10 minutes. To visualize proteins equal amounts of lysate were removed and the proteins
were separated by SDS-PAGE and the proteins visualized by western immunoblotting with
appropriate antibody as described below.
Immunoprecipitation
Equal amounts of cell lysate were incubated overnight at 4 °C with the appropriate antibody
(PY99, β3, Src kinase, FAK using a 1:500 dilution). Immune complexes were then
precipitated by adding protein A sepharose and incubating for a further 2 hours at 4 °C. The
samples were then centrifuged at 14,000 × g for 10 minutes and the pellets washed 4 times
with lysis buffer. The pellets were resuspended in 45 µl of reducing Laemmeli buffer (0.2M
final concentration DTT), boiled for 5 minutes and the proteins separated by SDS-PAGE,
8% gel.
Western Immunoblotting
Following SDS-PAGE the proteins were transferred to Immobilon P membranes. The
membranes were blocked in 1 % BSA in Tris-buffered saline with 0.1% Tween (TBST) for
2 hours at room temperature then incubated with the appropriate primary antibody (β3, c-
β3, Calpain 1, PY99, FAK, FAK[pY397], Syk or Src kinase and Src kinase [pY418], using a
1:500 dilution) overnight at 4°C and washed three times in TBST. Binding of the peroxidase
labeled secondary antibody was visualized using enhanced chemiluminescence following
the manufacturer’s instructions (Pierce, Rockford IL) and the immune complexes were
detected by exposure to autoradiographic film.
Chemiluminescent images obtained were scanned using a DuoScan T1200 (AGFA Brussels,
Belgium) and band intensities of the scanned images were analyzed using NIH Image,
Maile et al. Page 3













version 1.61. The Student’s t test was used to compare differences between treatments. The
results that are shown are representative of at least three separate experiments.
Results
Echistatin treatment alters tyrosine phosphorylation of the β3 subunit of αVβ3
Since echistatin binds directly to αVβ3 in SMC we first determined whether we could
identify a direct effect of echistatin on integrin activation[Jones et al., 1996]. β3
phosphorylation is a marker of the activation state of αVβ3[Ling et al., 2003; Maile et al.,
2001]. Consistent with our previous reports we detected basal β3 phosphorylation in
quiescent SMC (figure 1A; top panel) [Ling et al., 2003]. Following echistatin treatment,
there was a slight increase in β3 phosphorylation after 1 hour that was still apparent after 4
hours (a 2.0 ± 0.1 fold increase compared with cells not treated with echistatin ; mean ±
s.e.m, n = 3, p<0.05). However after a 5-hour exposure to echistatin β3 phosphorylation was
undetectable (figure 1A; top panel)
Echistatin treatment triggers cleavage of the β3 subunit of αVβ3
Immunoblotting of cell lysates from the same experiment revealed however, that there was a
significant decrease in the amount of β3 that could be detected after 7 hours treatment with
echistatin compared with cells incubated in SFM alone (a 79 ± 10 % decrease; mean ± s.e.m.
n =3, p <0.05). In addition the β3 that remained appeared to have increased electrophoretic
mobility on the SDS gel as the β3 immunoreactive band appeared to have a lower molecular
weight compared with the untreated control. The increase in mobility suggested a decrease
in the molecular weight of intact β3 protein following 5 and 7 hours of treatment.
Since it has been reported that the cytoplasmic tail of β3 is susceptible to proteolytic
cleavage [Du et al., 1995; Pfaff et al., 1999] we hypothesized that the changes in β3
detection following echistatin treatment may be due to the proteolytic cleavage. To assess
this we examined β3 protein levels using an antibody specific for the C-terminal region of
β3 [Du et al., 1995]. Treatment with echistatin for 5 and 7 hours resulted in a significant,
82.75 ± 5 % decrease (mean ± s.e.m. n =3; p<0.05), in the level of β3 protein detectable with
the antibody specific for the cytoplasmic domain (c-β3), compared with control cultures
(Figure 1C).
To compare the effects of the RGD antagonist with both intact Vn and a peptide
corresponding to the HBD region of Vn, SMC were also incubated for 7 hours either intact
Vn or the Vn HBD peptide. Both Vn and the Vn HBD peptides stimulated significant
increases (a 4.8 ± 1.3 fold increase compared with untreated cells; mean ± s.e.m. n = 3,
p<0.05) in β3 phosphorylation consistent with our previous studies [Maile et al., 2006b].
There was no significant difference in total β3 protein levels from cells incubated for 7 hours
in the presence or absence of Vn or the Vn HDB peptide and the molecular weight estimate
of β3 indicated that it remained intact (Figure 1B).
Effect of an αVβ3 specific synthetic analogue
Although our previous studies had suggested that echistatin binds primarily to αVβ3 on
smooth muscle cells [Jones et al., 1996] it can bind to other αV integrins so we determined if
cleavage could be stimulated by a synthetic analogue that binds specifically to αVβ3
[Clemmons et al., 1999]. We have reported previously that a synthetic αVβ3 antagonist
referred to as (SC69000) which blocks I125 kistrin binding to αVβ3 on SMC to an extent that
is comparable to echistatin [Clemmons et al., 1999], also inhibited IGF-I stimulated cell
migration and stimulated IGF-IR dephosphorylation. Exposure to SC69000 (10−6 M) for 7
hours reduced the levels of β3 protein detected with the cytoplasmic tail specific antibody by
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84 ± 12 % compared with untreated cells (mean ± s.e.m. n = 3, p <0.05), a level that was
comparable following treatment with echistatin (figure 1D). In contrast a control compound,
(SC64258), which had been shown to have no significant effect on I125 kistrin binding to
αVβ3 [Clemmons et al., 1999], had no significant effect on β3 cleavage (figure 1D).
Calpain activation is required for echistatin induced cleavage of β3
Activation of the protease calpain has been shown to result in cleavage of the β3
cytoplasmic tail and inhibition of this protease with E64d blocks cleavage [Du et al., 1995].
We therefore examined the effect of E64d on the echistatin induced decrease in β3
phosphorylation and cleavage of β3. Preincubation of cells with E64d prior to incubation
with echistatin completely restored β3 phosphorylation levels to that seen in the absence of
echistatin treatment (figure 1A; top panel). Similarly, E64d pretreatment inhibited the
echistatin induced cleavage of β3 (figure 1A; middle panel) since β3 protein levels in the
presence of E64d were 108 ± 1.5 % of control levels (mean ± s.e.m. n =3). This observation
was confirmed using the antibody to β3 that specifically recognizes the cytoplasmic tail
(figure 1C) (β3 protein levels were 105 ± 5 % of control levels (mean ± s.e.m. n = 3). In
these experiments there was no significant effect of E64d on β3 protein levels or
phosphorylation in the absence of echistatin treatment. Taken together with the results in
figure 1A this suggests that the decrease in β3 phosphorylation following echistatin
treatment is most likely due to the loss of the β3 cytoplasmic tail following proteolysis of
β3.
Echistatin activates Calpain
We next determined whether echistatin could directly activate calpain. A size shift (from
80kDa to a 74/76kDa doublet) in calpain has been shown to predict its activation as a result
of autoproteolytic cleavage [Saito et al., 1994]. No calpain 2 was detected (data not shown),
however, this may be due to a lack of antibody species cross reactivity since the antibody
that was used was directed against human calpain and the smooth muscle cells used in this
study were of porcine origin. In contrast, calpain 1 was clearly detected in the lysates (figure
2). Following a 4 hour incubation with echistatin there was a decrease in the amount of
intact (inactive) calpain and an increase in the amount of the smaller molecular weight
fragment of calpain (active). Analysis of data from three separate experiments revealed a 80
± 4 % decrease (mean ± s.e.m. n = 3) in intact calpain 1 and a corresponding, 84 ± 6 %
increase (mean ± s.e.m) in fragment following 7 hours treatment with echistatin (Figure 2).
This change was significantly greater compared to cells treated in SFM alone (p < 0.05).
Since autoproteolytic activity is a marker of calpain activation this result strongly suggests
that echistatin binding to the cell surface triggers and increase in calpain 1 activation. The
time course of activation shows that significant calpain activation has occurred after 5 and 7
hours incubation with echistatin; which is also the time of maximal β3 change in β3
cleavage.
Echistatin increases the phosphorylation of intracellular proteins
In order to investigate the pathway by which echistatin triggers activation of calpain and
thereby cleavage of β3 we examined signaling events that occur between 30 minutes and 5
hours following echistatin exposure. We first examined the total amount of phosphorylated
proteins in the SMC before and after echistatin treatment. Treatment of SMC with echistatin
stimulated an increase in two specific phosphoprotein bands in the range of 100–120kDa
and 70–80 kDa (figure 3 bottom panel). The increase in phosphorylation of the protein(s)
with a molecular weight estimate of 120kDa was first detectable after 1-hour treatment with
echistatin and the level of phosphorylation continued to increase with up to 4 hours
treatment (a 2 ± 0.2 fold increase compared with untreated cells; mean ± s.e.m. n = 3,
p<0.05) after which it remained unchanged. There was a small increase in the
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phosphorylation of the 70–80kDa band after 1-hour incubation with echistatin and the level
of phosphorylation increased further after 4 hours treatment then it appeared to remain
unchanged thereafter (a 1.8 ± 0.3 fold increase compared with untreated cells; mean ± s.e.m.
n = 3, p <0.05). Control blots of cell lysates demonstrated that there was no change in the
level of αV protein (figure 3 top panel) and that the level of β3 (as measured using the
antibody specific for the cytoplasmic tail of β3) decreases over the same time interval
(figure 3 middle panel). This suggests that the changes in levels of these two phosphorylated
proteins are not due to loading differences or changes in the level of total cellular protein.
Echistatin treatment results in the activation of FAK
It has been reported that activation of integrin receptors leads to the phosphorylation and
therefore autoactivation of focal adhesion kinase (FAK) a 125kDa protein [Kornberg et al.,
1992]. It has also been reported that binding of another αVβ3 disintegrin, contortrostatin, to
mammary carcinoma cells also increased FAK phosphorylation [Ritter et al., 2000]. Since
the increase in the 120kDa phosphoprotein band could be due to an increase in FAK
phosphorylation we determined whether an increase in FAK phosphorylation occurred in
response to echistatin. We examined the phosphorylation status of tyrosine 397 of FAK
specifically as this is the site of autophosphorylation and therefore represents the activated
form of FAK. Echistatin treatment resulted in a significant increase in the level of
autophosphorylated, FAK (figure 4A). This increase was initially detected following 1-hour
incubation with echistatin. A further increase was detected following 3–4 hours incubation
(a 4.06 ± 0.12 fold increase (mean ± s.e.m. n = 3), p<0.05 compared with SFM alone).
Activation of Src and Syk tyrosine kinases follows activation of FAK by echistatin
The phosphorylation and activation of FAK following integrin activation has been shown to
lead to the recruitment and phosphorylation of c-Src kinase [Schaller et al., 1994]. The
association of Src with FAK results in further FAK phosphorylation leading to full catalytic
activation. Therefore we next examined the effect of echistatin on c-Src activity using
phosphorylation of tyrosine 418 as a marker of its activation. A 1-hour treatment with
echistatin stimulated a 3.96 ± 0.3 fold increase in Src kinase phosphorylation (mean ± s.e.m.
n = 3, p<0.05 compared with SFM alone; figure 4B). This increased further following a 4-
hour incubation (a 7.7 fold ± 0.6 increase compared with cells treated in SFM alone; mean ±
s.e.m. n = 3, p<0.05 compared with SFM alone).
Activation of the tyrosine kinase Syk has been shown to be downstream of Src kinase
activation following integrin ligation [Kurosaki et al., 1994]. We therefore examined
whether the phosphorylation of Syk contributed to the phosphorylated protein band detected
at 70–80kDa following echistatin treatment. After 4 hours treatment with echistatin there
was a 2.0 ± 0.1 fold increase in Syk phosphorylation (mean ± s.e.m. n = 3, p<0.05 compared
with SFM alone; figure 4B).
Effect of calpain and c-Src kinase inhibitors on FAK and Syk activation
To determine whether activation of Src kinase was required for echistatin induced activation
of Fak and Syk, cells were preincubated with the Src kinase inhibitor PP2 and the effect of
echistatin induced phosphorylation of FAK and Syk was compared to cells that were not
preincubated with PP2. In the presence of PP2 the echistatin induced increase in FAK
phosphorylation was reduced by 50 ± 5 % (mean ± s.e.m. n = 3, p<0.05 compared with
echistatin alone). The presence of PP2 had no effect on the phosphorylation of FAK in the
absence of echistatin since FAK phosphorylation in the presence of PP2 was 96 ± 2 %
(mean ± s.e.m. n = ns) of the level of FAK phosphorylation in the absence of echistatin
treatment (figure 5A). E64d had no significant effect on the phosphorylation of FAK either
basally [FAK phosphorylation in the presence of E64d was 110 ± 15 % of the level in the
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absence of E64d treatment (mean ± s.e.m. n = 3, p, ns] or in the presence of echistatin (FAK
phosphorylation in the presence of echistatin and E64d was 120 ± 12 % of the level of FAK
phosphorylation following treatment with echistatin alone, [mean ± s.e.m. n = 3, p = ns
(Figure 5A)].
The presence of PP2 had no effect on Syk phosphorylation in the absence of echistatin since
Syk phosphorylation in the presence of PP2 was 102 ± 3 % (mean ± s.e.m. n = 3, p = ns) of
the level of Syk phosphorylation in untreated cells. Pretreatment of cells with PP2 prior to
the addition of echistatin completely inhibited the increase in Syk phosphorylation [Syk
phosphorylation in the presence of echistatin plus PP2 was reduced by 57 ± 6 % [mean ±
s.e.m n = 3, p = ns (figure 5B)]. This suggests that activation of Src kinase is upstream of the
activation of Syk and that the activation of Src kinase contributes to some but not all of the
phosphorylation of FAK. E64d had no significant effect on the phosphorylation status of
Syk either basally or in the presence of echistatin Syk phosphorylation in the presence of
echistatin plus E64d was 97 ± 4 % of the level of Syk phosphorylation following treatment
with echistatin alone [mean ± s.e.m n = 3, p = ns (figure 5B)] suggesting that the activation
of calpain is downstream of the activation of Src and Syk kinase activity (figure 5 A&B).
Inhibition of Syk inhibits echistatin induced β3 cleavage
In order to determine whether the activation of signaling components in this pathway were
involved in the echistatin induced activation of calpain and cleavage of β3 we examined the
effects of PP2 and the Syk kinase inhibitor, piceatannol, on echistatin induced activation of
calpain 1 and on cleavage of β3. The 82.75 ± 5 % decrease in β3 protein levels (as
determined by immunoblotting with the antibody that recognizes the cytoplasmic tail of β3)
following a 7-hour incubation with echistatin was effectively blocked in the presence of
PP2, piceatannol and calpastatin (with β3 protein levels being 92 ± 5, 95 ± 4.7 and 91 ± 8 %
of controls respectively; mean ± s.e.m n = 3; figure 6A). Each inhibitor had no significant
effect on β3 protein levels in the absence of echistatin treatment.
The decrease in intact calpain 1 levels and increase in the lower molecular weight forms of
calpain that are detected following echistatin treatment was inhibited by the Src family
kinase inhibitor, PP2 and the Syk inhibitor piceatannol, while neither inhibitor had any
effect on calpain activation in the absence of echistatin treatment (figure 6B). While we
observed a certain degree of experiment-to-experiment variation in the basal level of calpain
activity, echistatin treatment consistently resulted in conversion to the active fragment
comprising >90 % of the total detectable calpain. This change was consistent and the
increase was significant compared with the cells incubated in the absence of echistatin (p
<0.05). Regardless of the basal level of calpain activity the Src and Syk inhibitors
consistently inhibited the formation of the active fragment and the level of intact calpain was
comparable to control cultures (figure 6B).
Taken together the results shown are consistent with the conclusion that the activation of Src
and Syk is upstream of the activation of calpain and is required for calpain activation and
subsequent cleavage of β3.
The Vn HBD negates the ability of SC69000 to activate Syk
Intact Vn binds to αVβ3 through both its RGD and HBD sequences. RGD peptides
antagonize IGF-I signaling whereas the Vn HBD enhances IGF-I stimulated signaling in
SMC [Maile et al., 2006b]. Furthermore, intact Vn enhances IGF-I signaling even though it
binds αVβ3 through its RGD and HBD sequences [Maile et al., 2006b]. Since the effect of
the Vn HBD peptide is comparable to the effect of intact Vn these findings raise the
question as to whether binding of the Vn HBD region modulates the apparent inhibitory
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effect that is induced by ligand binding to the RGD binding site, on IGF-I mediated
signaling. Having characterized the signaling events that are activated following incubation
with echistatin we were able to address this question. We first compared Syk activation by
SC69000 in the presence or absence of either the VnHBD peptide or intact Vn. SC69000
induced a 2.4 ± 0.3 (mean s.e.m, n = 3 p < 0.05) fold increase in Syk phosphorylation which
was completely inhibited in the presence of either intact Vn or the Vn HBD peptide (Syk
phosphorylation was increased in the presence of Vn or the Vn HBD 1.2 ± 0.4 fold
compared with untreated cells, p, ns) (figure 7A top panel).We next examined β3 cleavage
and consistent with the role of Syk in activating the signaling pathway that leads to β3
cleavage following RGD site antagonist binding, the 3 ± 0.12 fold decrease in intact β3
protein that was stimulated by SC69000 was blocked in the presence of intact Vn or the
VnHBD peptide (figure 7A middle panel).
To determine the relative roles of the VnHBD and RGD sequences within the context of the
whole Vn molecule we compared the effect of adding a Vn mutant in which the HBD had
been deleted (VnΔHBD) with a Vn mutant in which the RGD sequence had been changed to
RGE (VnRGE), on SC69000 mediated signaling. Vn RGE alone had no effect on Syk
activation. Syk activation in the presence Vn RGE was increased 1.1 ± 0.1 compared with
untreated cells (p, ns). The addition of Vn RGE however, completely inhibited the effect of
SC69000 on Syk activation. In contrast to the 3.7 ± 0.4 fold increase in Syk activation in the
presence of SC69000, Syk activation in the presence of Vn RGE was not significantly
different from untreated cells (1.1 ± 0.1 fold increase compared with untreated cells, p = ns).
The inhibition of Syk activation was reflected in the complete inhibition of the 74 ± 4 %
decrease in intact β3 protein since β3 protein in the presence of Vn RGE was 110 ± 9 % of
untreated cells (mean ± s.e.m, n = 3, p<0.05). In contrast addition of the VnΔHBD deletion
mutant activated Syk to a similar extent as SC69000 (a 3.5 ± .2 fold increase in Syk
activation compared with untreated cells, (mean ± s.e.m, n = 3, p <0.05) and exposure to
VnΔHBD was associated with a 92 ± 8 % decrease in β3 protein levels (mean ± s.e.m. n = 3,
p <0.05). Furthermore, VnΔHBD was unable to inhibit the effect of SC69000 in stimulating
Syk activation and it had no effect on SC69000 stimulated β3 cleavage (figure 7B). Syk
activation was increased by 3.4 ± 4 fold in the presence of SC69000 and VnΔHBD
compared with untreated cells (mean ± s.e.m. n = 3, p<0.05). Similarly β3 protein levels
were reduced by 76 ± 6 % in the presence of SC69000 and Vn ΔHBD compared with
untreated cells.
Since activation of calpain by echistatin is critical for its effects on β3 cleavage we wished
to determine the effect of the RGD sequence within intact Vn and the modulatory role of the
HBD sequence on calpain activation. When SMC were treated with intact Vn or VnRGE
calpain activation was not significantly changed compared with untreated cells. In contrast
when SMC were incubated with VnΔHBD a 72 ± 9 % decrease in intact calpain and a
corresponding 84 % increase in calpain fragment, (mean ± s.e.m. n = 3, p<0.05) could be
detected indicative of calpain activation (Figure 7B).
Discussion
Echistatin was first described as an antagonist of integrin function acting to block fibrinogen
binding to platelets thereby inhibiting platelet aggregation [Gan et al., 1988]. Our results
show that in addition to a passive antagonist function echistatin also actively stimulates
signaling events through its binding to the αVβ3 integrin without causing detachment of
stably attached SMC. This is consistent with a previous report in which it was observed that
echistatin triggered an apoptotic response in breast cancer cells prior to initiating detachment
[Brassard et al., 1999]. Signaling initiated by disintegrin binding specifically to αVβ3 has
also been reported for the disintegrin contortrostatin [Ritter et al., 2001]. In that report
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contortrostatin was shown to stimulate hyperphosphorylation of FAK and it disrupted the
actin cytoskeleton and causing disassembly of focal adhesions without affecting cell
adhesion [Ritter et al., 2001]. Echistatin binding to αVβ3 has been shown to induce
conformational changes that result in increased ligand induced binding sites [Marcinkiewicz
et al., 1997]. These conformational changes lead to a further increase in binding affinity for
echistatin. Ligand binding of ECM proteins to the integrin receptors also induces
conformational changes that contribute to the activation of intracellular signaling pathways,
a process that has been termed “outside in signaling” [Aplin et al., 1999]. Therefore it is
likely that the conformational changes induced by echistatin binding are sufficient to initiate
outside in signaling. In this study we demonstrate that echistatin binding to αVβ3 leads to
outside in signaling as reflected in the sequential activation of FAK, Src and Syk leading to
calpain activation and ultimately β3 cleavage.
FAK phosphorylation has been shown to be stimulated following integrin agonist binding
and to be required for focal adhesion stability. It is also essential for cell migration in many
systems [Gilmore and Romer, 1996;Sieg et al., 1999]. Our data and that of Ritter et al
discussed above [Ritter et al., 2001] demonstrate that integrin antagonists can also trigger
the phosphorylation of FAK yet they function to inhibit integrin mediated effects such as
cell migration. These responses are somewhat inconsistent with the previous described role
for FAK. However, while phosphorylation of FAK is essential for its role in regulating
cellular responses other studies have also suggested its rate of dephosphorylation is equally
important [Sieg et al., 1999;Gilmore and Romer, 1996]. For example, it has is been shown
that in cells expressing a mutant form of SHP-2, which is catalytically inactive, IGF-I cannot
stimulate cell migration and this response is associated with a reduction in IGF-I stimulated
FAK dephosphorylation [Manes et al., 1999]. This is consistent with our own observations
using cells that express mutant forms of β3, that are not activated by ligand occupancy in
which inhibition of IGF-I stimulated cell migration is associated with inhibition of IGF-I
stimulated FAK dephosphorylation [Maile et al., 2001]. Additionally expression of the
mutant forms of β3 is associated with a lack of SHP-2 recruitment to β3 and its subsequent
transfer to SHPS-1 [Maile and Clemmons, 2002]. If, as these studies would suggest, SHP-2
recruitment to β3 is necessary for the dephosphorylation of FAK then echistatin induced
cleavage of the cytoplasmic tail of β3 due to calpain activation would be predicted to result
in an inability of IGF-I to stimulate FAK dephosphorylation as a result of the spatial and
temporal dysregulation of SHP-2 transfer. This suggests that the activation state of the
integrin is not only a regulator of FAK phosphorylation but that it also regulates FAK
dephosphorylation via its ability to regulate the distribution of SHP-2.
Calpain 1 a member of the calpain family of calcium dependent cysteine proteases is a
ubiquitous protease that has been shown to be localized to focal adhesions of various types
of adherent cells [Glading et al., 2002; Perrin and Huttenlocher, 2002]. Studies have shown
that activation of calpain results in the limited proteolysis of various structural and signaling
molecules that are co-localized in focal adhesions [Cooray et al., 1996; Fox et al., 1985]. As
such calpain has been implicated in remodeling of cytoskeletal and membrane attachments.
However, dysregulation of calpain activity results in tissue damage in response to events
such as myocardial infarction, stroke, and brain trauma [Goll et al., 2003]. Previous studies
have reported that calpain activation is an event that is downstream of integrin activation
[Fox et al., 1985]. Furthermore, it was shown that calpain is necessary for the formation of
integrin clusters, which accumulate prior to the formation of focal adhesion complexes
[Bialkowska et al., 2000]. In addition those clusters were shown to contain calpain cleaved
β3. Other studies have shown that β3 is a target for proteolytic cleavage by calpain and more
specifically that the cytoplasmic tail of β3 has been shown to have a number of calpain
cleavage sites; the two major sites flank the two tyrosine phosphorylation motifs [Du et al.,
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1995; Pfaff et al., 1999]. Studies have shown that the cleavage of β3 is involved in clot
retraction since calpain activation was shown to result in marked reduction in platelet-
mediated clot retraction while inhibition of calpain prevented this effect [Schoenwaelder et
al., 1997]. The effects of calpain were associated with cleavage of Src and talin and the
associated disruption of integrin – cytoskeletal attachment is likely to contribute to the
effects of calpain on clot retraction. Additionally, the calpain mediated cleavage of β3 has
been shown to be an early event in detachment triggered apoptosis in endothelial cells
[Meredith et al., 1998]. These previous studies suggest that calpain is an important regulator
of cellular events that are regulated by integrin engagement. Our results demonstrate that
activation of the αVβ3 integrin following disintegrin binding can lead to a level of calpain
activation that can result in significant β3 cleavage. Since we have determined previously
that recruitment of signaling molecules such as DOK-1 to β3 is required for IGF-I mediated
signaling [Ling et al., 2005] these observations provide a mechanism by which echistatin
treatment inhibits signaling events that are stimulated by IGF-I. To our knowledge this is the
first report to describe the consequences of calpain mediated cleavage of an integrin
cytoplasmic domain on growth factor stimulated signaling.
The obvious question from our studies is why does echistatin binding to αVβ3 and activation
of FAK lead to calpain activation and β3 cleavage whereas αVβ3 ligand occupancy with Vn
or osteopontin does not result in these changes? We determined previously that the
enhancing effect of Vn on IGF-I signaling was dependent upon binding of its HBD but not
its RGD region to αVβ3 since addition of a VnΔHBD mutant could not enhance IGF-I
mediated signaling whereas the Vn RGE mutant was fully active [Maile et al., 2006b]. In
this study we extend those observations to show that a peptide containing the HBD of Vn
can inhibit the signaling events that are initiated by RGD antagonists. This effect was not
limited to a Vn HBD peptide but was also apparent when the Vn RGE mutant, which also
binds to the region of β3 that binds the HBD peptide [Maile et al., 2006a; Maile et al.,
2006b], was analyzed. Specifically, this mutant negated the effects of SC69000 on Syk
activation and β3 cleavage. Furthermore, while incubation of SMC with wild-type Vn or the
Vn RGE mutant had no effect on calpain activation, treatment of SMC with the VnΔHBD
mutant caused a significant increase in calpain activation similar to that seen following
treatment of cells with the RGD containing antagonists. These results suggest that the effect
of αVβ3 ligand occupancy is a balance between signaling events that are triggered by Vn
binding to both its RGD and HBD sequences. The results support the conclusion that under
usual conditions the net effect of the intact Vn molecule is to inhibit Syk and thus calpain
activation as well as β3 cleavage even though it binds to the RGD binding site. In contrast a
mutant form of Vn that did not have the HBD domain could not counteract the effect of the
RGD antagonist on β3 cleavage. This clearly demonstrates that the HBD domain of Vn
contains the sequence that confers this inhibitory property and that when intact Vn binds to
αVβ3 this inhibitory effect on Syk/calpain activation predominates.
The suggested role of αVβ3 in angiogenesis, atherosclerosis, and metastasis has lead to
widespread interest in the use of αVβ3 inhibitors as treatments for these conditions. The
results from these studies extend our understanding of the complexity of αVβ3 signaling and
suggest that using RGD antagonists that activate this specific series of intracellular signaling
events may be a less desirable approach as compared to blocking the signaling effects that
occur following binding of the Vn HBD region [Maile et al., 2006a; Maile et al., 2006b].
Acknowledgments
This work was funded by a National Institute of Health grant HL56850 to D.R.C. and an American Heart
Association Mid Atlantic Affiliate Beginning Grant in Aid (0465462U) to L.A.M.
Maile et al. Page 10














Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell
adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and
selectins. Pharmacol Rev. 1998; 50:197–263. [PubMed: 9647866]
Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr
Opin Cell Biol. 1999; 11:737–744. [PubMed: 10600702]
Bialkowska K, Kulkarni S, Du X, Goll DE, Saido TC, Fox JE. Evidence that beta3 integrin-induced
Rac activation involves the calpain-dependent formation of integrin clusters that are distinct from
the focal complexes and focal adhesions that form as Rac and RhoA become active. J Cell Biol.
2000; 151:685–696. [PubMed: 11062268]
Blobel CP, White JM. Structure, function and evolutionary relationship of proteins containing a
disintegrin domain. Curr Opin Cell Biol. 1992; 4:760–765. [PubMed: 1419054]
Brassard DL, Maxwell E, Malkowski M, Nagabhushan TL, Kumar CC, Armstrong L. Integrin
alpha(v)beta(3)-mediated activation of apoptosis. Exp Cell Res. 1999; 251:33–45. [PubMed:
10438569]
Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A, Nickols GA. Synthetic alphaVbeta3
antagonists inhibit insulin-like growth factor-I- stimulated smooth muscle cell migration and
replication. Endocrinology. 1999; 140:4616–4621. [PubMed: 10499518]
Cooray P, Yuan Y, Schoenwaelder SM, Mitchell CA, Salem HH, Jackson SP. Focal adhesion kinase
(pp125FAK) cleavage and regulation by calpain. Biochem J. 1996; 318(Pt 1):41–47. [PubMed:
8761450]
Du X, Saido TC, Tsubuki S, Indig FE, Williams MJ, Ginsberg MH. Calpain cleavage of the
cytoplasmic domain of the integrin beta 3 subunit. J Biol Chem. 1995; 270:26146–26151. [PubMed:
7592818]
Fox JE, Goll DE, Reynolds CC, Phillips DR. Identification of two proteins (actin-binding protein and
P235) that are hydrolyzed by endogenous Ca2+-dependent protease during platelet aggregation. J
Biol Chem. 1985; 260:1060–1066. [PubMed: 2981831]
Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin. A potent platelet aggregation
inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988; 263:19827–19832.
[PubMed: 3198653]
Gilmore AP, Romer LH. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions
decreases cell motility and proliferation. Mol Biol Cell. 1996; 7:1209–1224. [PubMed: 8856665]
Glading A, Lauffenburger DA, Wells A. Cutting to the chase: calpain proteases in cell motility. Trends
Cell Biol. 2002; 12:46–54. [PubMed: 11854009]
Gockerman A, Prevette T, Jones JI, Clemmons DR. Insulin-like growth factor (IGF)-binding proteins
inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology. 1995;
136:4168–4173. [PubMed: 7545099]
Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003; 83:731–801.
[PubMed: 12843408]
Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the alpha-V-beta3 integrin is
necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl
Acad Sci U S A. 1996; 93:2482–2487. [PubMed: 8637900]
Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL. Cell adhesion or integrin clustering
increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem. 1992;
267:23439–23442. [PubMed: 1429685]
Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, Yamamura H. Syk
activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994;
179:1725–1729. [PubMed: 7513017]
Ling Y, Maile LA, Badley-Clarke J, Clemmons DR. DOK1 mediates SHP-2 binding to the
alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured
vascular smooth muscle cells. J Biol Chem. 2005; 280:3151–3158. [PubMed: 15546884]
Ling Y, Maile LA, Clemmons DR. Tyrosine Phosphorylation of the {beta}3-Subunit of the
{alpha}V{beta}3 Integrin Is Required for Membrane Association of the Tyrosine Phosphatase
Maile et al. Page 11













SHP-2 and Its Further Recruitment to the Insulin-Like Growth Factor I Receptor. Mol Endocrinol.
2003; 17:1824–1833. [PubMed: 12791772]
Maile LA, Badley-Clarke J, Clemmons DR. Structural analysis of the role of the beta 3 subunit of the
alpha V beta 3 integrin in IGF-I signaling. J Cell Sci. 2001; 114:1417–1425. [PubMed: 11257007]
Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Clemmons DR. IGF-I
signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184
sequence of the {beta}3 subunit of {alpha}V{beta}3. Mol Endocrinol. 2006a; 20:881–892.
[PubMed: 16322097]
Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Ling Y, Clemmons DR. The
heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth
factor-I signaling. Mol Endocrinol. 2006b; 20:405–411. [PubMed: 16195248]
Maile LA, Clemmons DR. The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I)
receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing
phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocr J. 2002; 143:4259–4264.
Manes S, Mira E, Gomez-Mouton C, Zhao ZJ, Lacalle RA, Martinez AC. Concerted activity of
tyrosine phosphatase SHP-2 and focal adhesion kinase regulation of cell motility. Mol Cell Biol.
1999; 4:3125–3135. [PubMed: 10082579]
Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-
terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and
expression of ligand-induced binding site. Blood. 1997; 90:1565–1575. [PubMed: 9269775]
Meredith J Jr, Mu Z, Saido T, Du X. Cleavage of the cytoplasmic domain of the integrin beta3 subunit
during endothelial cell apoptosis. J Biol Chem. 1998; 273:19525–19531. [PubMed: 9677375]
Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ. Disintegrins and other naturally occurring
antagonists of platelet fibrinogen receptors. Semin Hematol. 1994; 31:289–300. [PubMed:
7831574]
Perrin BJ, Huttenlocher A. Calpain. Int J Biochem Cell Biol. 2002; 34:722–725. [PubMed: 11950589]
Pfaff M, Du X, Ginsberg MH. Calpain cleavage of integrin beta cytoplasmic domains. FEBS Lett.
1999; 460:17–22. [PubMed: 10571053]
Ritter MR, Zhou Q, Markland FS Jr. Contortrostatin, a snake venom disintegrin, induces alphavbeta3-
mediated tyrosine phosphorylation of CAS and FAK in tumor cells. J Cell Biochem. 2000; 79:28–
37. [PubMed: 10906753]
Ritter MR, Zhou Q, Markland FS Jr. Contortrostatin, a homodimeric disintegrin, actively disrupts focal
adhesion and cytoskeletal structure and inhibits cell motility through a novel mechanism. Cell
Commun Adhes. 2001; 8:71–86. [PubMed: 11771727]
Saito Y, Saido TC, Sano K, Kawashima S. The calpain-calpastatin system is regulated differently
during human neuroblastoma cell differentiation to Schwannian and neuronal cells. FEBS Lett.
1994; 353:327–331. [PubMed: 7957886]
Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the
focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol.
1994; 14:1680–1688. [PubMed: 7509446]
Schoenwaelder SM, Kulkarni S, Salem HH, Imajoh-Ohmi S, Yamao-Harigaya W, Saido TC, Jackson
SP. Distinct substrate specificities and functional roles for the 78- and 76-kDa forms of mu-calpain
in human platelets. J Biol Chem. 1997; 272:24876–24884. [PubMed: 9312088]
Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-
stimulated cell migration. J Cell Sci. 1999; 112(Pt 16):2677–2691. [PubMed: 10413676]
Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgren Y, Ruoslahti E. Domain structure of
vitronectin. Alignment of active sites. J Biol Chem. 1984; 259:15307–15314. [PubMed: 6210287]
Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL,
Arnaout MA. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science.
2001; 294:339–345. [PubMed: 11546839]
Yoneda A, Kojima K, Matsumoto I, Yamamoto K, Ogawa H. Porcine vitronectin, the most compact
form of single-chain vitronectin: the smallest molecular mass among vitronectins was ascribed to
deletion and substitution of base pairs, and proteolytic trimming of the peptide. J Biochem
(Tokyo). 1996; 120:954–960. [PubMed: 8982862]
Maile et al. Page 12













Zheng B, Clemmons DR. Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin- like
growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci U S A. 1998;
95:11217–11222. [PubMed: 9736716]
Maile et al. Page 13













Figure 1. Echistatin treatment triggers the cleavage of the β3 subunit of αVβ3
SMC were incubated for various times as indicated with echistatin (10−8M), vitronectin
(Vn; 2 µg/ml) Vn HBD (10µg/ml), SC69000 or SC64258 (10−6M). In some cases SMC
were preincubated with E64d (20µM) for 1 hour prior to the addition of the other
compounds.
A: Following lysis and immunoprecipitation with an anti-β3 antibody, phosphorylation of
β3 was determined by immunoblotting with an anti-phosphotyrosine antibody (p-Tyr). Equal
amounts of total protein from cell lysates were analyzed and the amount of β3 was
determined by immunoblotting with an anti-β3 antibody. To control for loading the amount
of αV protein in each sample is also shown.
B: Aliquots of cell lysates from the same experiment as described in panel A were
immunoblotted with an antibody specific for the cytoplasmic tail of β3 (c- β3). To control
for loading the amount of αV protein in each sample is also shown.
C: Following lysis and immunoprecipitation with an anti-β3 antibody, phosphorylation of
β3 was determined by immunoblotting with an anti-phosphotyrosine antibody (p-Tyr). Equal
amounts of total protein from cell lysates were analyzed and the amount of β3 was
determined by immunoblotting an antibody specific for the cytoplasmic tail of β3 (c- β3). To
control for loading the amount of αV protein in each sample is also shown.
D: SMC were treated as indicated for 7 hours. Following cell lysis β3 was visualized using
an antibody specific for the cytoplasmic tail of β3 (c- β3). To control for loading the amount
of αV protein in each sample is also shown.
The data in these figures are representative of the results from three similar experiments.
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Figure 2. Activation of calpain following incubation with echistatin
A: SMC in SFM were treated with echistatin (10−8M) for various times as indicated.
Following cell lysis calpain 1 levels were determined by immunoblotting with a specific
antibody. The arrows indicate the positions of intact calpain and the autoproteolytic calpain
fragment. The data in this figure are representative of the results from three similar
experiments.
B: The decrease in intact calpain 1 protein levels and the associated increase in fragment as
determined by scanning densitometric analysis of western immunoblots from three
independent experiments is shown. ** p <0.05 when the level of intact calpain 1 after 7
hours treatment is compared with 7 hours treatment in SFM alone.
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Figure 3. Echistatin stimulation of protein tyrosine phosphorylation
A: SMC were incubated in SFM with or without the addition of echistatin (10−8M) for
various lengths of time as indicated. Cells were then lysed and immunoprecipitation
performed with an anti-phosphotyrosine antibody (p-Tyr). This was followed by
immunoblotting with the same anti-phosphotyrosine antibody. The level of αV as
determined by immunoblotting of aliquots of cell lysates from the same experiment is shown
in the upper panel and the level of β3 as determined by immunoblotting with the antibody
specific for the c-terminal of β3 is shown in the middle panel (c- β3). The data in this figure
are representative of the results from three similar experiments.
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Figure 4. Echistatin stimulation of FAK, c-Src and Syk phosphorylation
SMC were incubated in SFM with or without the addition of echistatin (10−8M) for various
lengths of time as indicated. Cells were then lysed and immunoprecipitated with A) an anti-
FAK antibody followed by immunoblotting with an antibody specific for the phosphorylated
form of FAK [pY397] (pFAK), B) an anti-c-Src antibody followed by immunoblotting with
an antibody specific for the active form of c-Src [pY418] (pSrc) and C) an anti-
phosphotyrosine antibody (p-Tyr) and immunoblotting with an anti-Syk antibody. Equal
amounts of lysates were also immunoblotted directly with appropriate antibody to control
for differences in protein. The data in these figures are representative of the results from
three similar experiments.
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Figure 5. Inhibition of c-Src inhibits FAK and Syk activation by echistatin
A: SMC were pretreated with PP2 (4 µM) or E64d (20 µM) where indicated prior to
treatment with or without echistatin (10−8M) for 5 hours. Cells were then lysed and
immunoprecipitation was performed with an anti-FAK antibody. This was followed by
immunoblotting with an antibody specific for the phosphorylated form of FAK [pY397]
(pFAK). Equal volumes of cell lysate were immunoblotted directly with an anti-FAK
antibody.
B: SMC were pretreated with PP2 (4 µM) or E64d (20 µM) where indicated prior to
treatment with or without echistatin (10−8M) for 4 hours. Cells were then lysed and
immunoprecipitation was performed with an anti-phosphotyrosine antibody. This was
followed by immunoblotting with an antibody specific Syk. Equal volumes of cell lysate
were immunoblotted directly with an anti Syk antibody.
The results shown are from the same gel but discontinuous lanes and the data are
representative of the results from three similar experiments.
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Figure 6. Inhibition of β3 cleavage and calpain activation by inhibitors of Src and Syk kinase
A: SMC in SFM were pretreated with PP2 (4 µM), piceatannol (30 µM) or calpastatin (50
µM) for 1 hour prior to a 7 hour incubation with echistatin (10−8M). Following cell lysis β3
protein levels in each sample were determined by immunoblotting with an antibody specific
for the cytoplasmic tail of β3 (c-β3). Data derived from scanning densitometric analysis
expressed as arbitrary scanning units: Lane 1: 31,546, Lane 2: 9433, Lane 3: 20755, Lane 4:
30576, Lane 5: 30832, Lane 6: 28851, Lane 7: 33672, Lane 8: 34078.
To control for total protein levels the amount of αV in each sample is also shown. The data
in this figure are representative of the results from three similar experiments.
B: SMC in SFM were pretreated with PP2 (4 µM) or piceatannol (30 µM) for 1 hour prior to
a 7 hour incubation with echistatin (10−8M). Following cell lysis pre and post autolytic
calpain protein levels were visualized in each sample by immunoblotting with an anti-
calpain 1 antibody. The arrows denote the position of intact calpain and its autolytic
fragments. To control for total protein levels the amount of αV in each sample is also shown.
The data in this figure are representative of the results from three similar experiments.
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Figure 7. Vn and the VnHBD inhibit the effects of RGD antagonism
SMC were incubated for with SC69000 (10-6M), wild-type vitronectin (Vn; 2 µM/ml), Vn
HBD (10µg/ml), VnRGE or VnΔ HBD (2 µg/ml) as indicated.
A &B: Cells were then lysed and immunoprecipitation performed with an anti-
phosphotyrosine antibody. This was followed by immunoblotting with an antibody specific
Syk (top panel). The level of intact β3, as determined by immunoblotting with the antibody
specific for the c-terminal of β3 (c-β3) is shown in the middle panel. Equal amounts of cell
lysate were immunoblotted directly with an anti-Syk antibody (bottom panel). The results
shown are from the same gel but discontinuous lanes and the data are representative of
results obtained from three independent experiments.
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C: Following cell lysis pre and post autolytic calpain protein levels were visualized in each
sample by immunoblotting with an anti-calpain 1 antibody. The arrows denote the position
of intact calpain and its autolytic fragments. To control for total protein levels the amount of
αV in each sample is also shown.
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